ASTX 660

Drug Profile

ASTX 660

Alternative Names: ASTX660

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astex Therapeutics
  • Developer Astex Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Inhibitor of apoptosis protein inhibitors; X-linked inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lymphoma; Solid tumours

Most Recent Events

  • 20 Nov 2017 Phase-II clinical trials in Lymphoma in USA (PO) (Otsuka Pharmaceutical pipeline, November 2017)
  • 20 Nov 2017 Phase-II clinical trials in Solid tumours (Late-stage disease) in USA (PO) (Otsuka Pharmaceutical pipeline, November 2017)
  • 27 Oct 2017 Safety and pharmacokinetics data from a phase I/II clinical trial in Solid tumours and Lymphoma presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top